Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share

Tarsus Pharmaceuticals, Inc.

2025-Q3 EPS reported -$1.40 revenue$299,692,000

XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.
Net loss of $12.6M vs $23.4M; diluted EPS $(0.30) vs $(0.61) in prior-year quarter.
Cash, equivalents & marketable securities of $401.8M as of Sept 30, 2025.
Phase 2 trial of TP-04 for ocular rosacea starting Dec 2025; Phase 2 of TP-05 for Lyme disease in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.